Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VSTM 
Verastem Inc (VSTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VSTM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.38
1 Year Target Price $15.38
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.16% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 475.75M USD | Price to earnings Ratio - | 1Y Target Price 15.38 |
Price to earnings Ratio - | 1Y Target Price 15.38 | ||
Volume (30-day avg) 9 | Beta 0.83 | 52 Weeks Range 2.32 - 9.10 | Updated Date 08/15/2025 |
52 Weeks Range 2.32 - 9.10 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.88 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) -2047.92% |
Management Effectiveness
Return on Assets (TTM) -64.8% | Return on Equity (TTM) -437.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 396137937 | Price to Sales(TTM) 222.62 |
Enterprise Value 396137937 | Price to Sales(TTM) 222.62 | ||
Enterprise Value to Revenue 185.37 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 61545300 | Shares Floating 45306551 |
Shares Outstanding 61545300 | Shares Floating 45306551 | ||
Percent Insiders 0.82 | Percent Institutions 87.71 |
Upturn AI SWOT
Verastem Inc
Company Overview
History and Background
Verastem, Inc. (VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of cancer patients. It was founded in 2010. Key milestones include clinical trials for its lead products and regulatory approvals. The company has evolved from a research-focused entity to a commercial-stage biopharmaceutical company.
Core Business Areas
- Oncology Drug Development: Focuses on the development of new treatments for cancers with unmet medical needs.
- Commercialization: Markets and sells its approved cancer therapies to healthcare providers and patients.
- Research and Development: Performs research to identify new drug targets and potential therapies.
Leadership and Structure
The leadership team includes the CEO, CFO, CMO and other senior management. The organizational structure consists of various departments including research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Defactinib: A FAK inhibitor. While previously partnered with Merck KGaA, Verastem has regained the rights. Clinical development continues with a focus on combination therapies. Competitors include other FAK inhibitors under development by other companies such as Bristol Myers Squibb. Revenue is currently $0.
- Mafedtorsen (formerly VS-6766): Mafedtorsen is a RAF/MEK inhibitor currently in clinical development for RAS-mutant cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer and others. Competition includes other MEK inhibitors like trametinib (GSK) and binimetinib (Array BioPharma, acquired by Pfizer). Market share data is currently evolving during the clinical development phase, not yet commercialized. Revenue is currently $0.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth, driven by advancements in research and development, aging populations, and increased healthcare spending. The oncology segment is a major driver of this growth.
Positioning
Verastem Inc. is positioned as a company focused on developing and commercializing novel cancer therapies. Its competitive advantage lies in its targeted therapies and clinical development pipeline.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars globally. Verastem Inc. is focused on specific segments within this market, targeting RAS-mutant cancers and other areas with unmet needs.
Upturn SWOT Analysis
Strengths
- Novel Targeted Therapies
- Strong Clinical Development Pipeline
- Experienced Management Team
- Potential for Market Exclusivity
Weaknesses
- Limited Commercial Infrastructure
- Reliance on Clinical Trial Success
- High R&D Expenses
- Dependence on Financing
Opportunities
- Expansion into New Cancer Indications
- Partnerships with Larger Pharmaceutical Companies
- Accelerated Regulatory Approvals
- Increasing Demand for Targeted Therapies
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Pricing Pressures
Competitors and Market Share
Key Competitors
- GSK
- PFE
- BMY
Competitive Landscape
Verastem Inc. faces intense competition from larger, established pharmaceutical companies. Its success depends on its ability to differentiate its products and effectively commercialize them.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and partnerships. Volatility is very high.
Future Projections: Future growth is dependent on the successful commercialization of its products and the expansion of its pipeline. Analyst estimates vary widely. Revenue projected to grow signficantly if Mafedtorsen is approved.
Recent Initiatives: Recent initiatives include advancing clinical trials for Mafedtorsen, Defactinib and seeking regulatory approval.
Summary
Verastem Inc. is a high-risk, high-reward biopharmaceutical company with a promising pipeline of targeted cancer therapies. Its future success depends on the positive outcomes of its clinical trials and regulatory approvals. The company's limited commercial infrastructure and reliance on external funding pose significant challenges. It needs to partner effectively to mitigate risks and to successfully market its therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Verastem Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verastem Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2012-01-27 | President, CEO & Director Mr. Daniel W. Paterson | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.verastem.com |
Full time employees 78 | Website https://www.verastem.com | ||
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.